Erasca (ERAS) Total Non-Current Liabilities (2020 - 2026)

Erasca (ERAS) posted Total Non-Current Liabilities of $67.4 million for Q1 2026, down 4.56% on a QoQ basis from $70.6 million in Q4 2025, and down 5.77% year-over-year from $71.5 million in Q1 2025.

Erasca (ERAS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Erasca's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $67.4 million for Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 5.77% year-over-year to $67.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.4 million (down 5.77% YoY) and the FY2025 annual result came in at $70.6 million, down 10.27% from the prior year.
  • Total Non-Current Liabilities was $67.4 million for Q1 2026 at Erasca, down from $70.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $102.5 million in Q4 2022 and bottomed at $67.4 million in Q1 2026.
  • A 5-year average of $77.5 million and a median of $77.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 129.12% — and 2023, when it declined 23.85%.
  • Erasca's Total Non-Current Liabilities stood at $102.5 million in 2022, then decreased by 23.85% to $78.0 million in 2023, then gained by 0.79% to $78.7 million in 2024, then fell by 10.27% to $70.6 million in 2025, then slipped by 4.56% to $67.4 million in 2026.
  • Business Quant data shows ERAS's Total Non-Current Liabilities at $67.4 million in Q1 2026, $70.6 million in Q4 2025, and $72.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Erasca 5.89 Bn 5.89 Bn - 67.37 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 67.37 Mn
Dec 31, 2025 70.58 Mn
Sep 30, 2025 72.12 Mn
Jun 30, 2025 72.87 Mn
Mar 31, 2025 71.49 Mn
Dec 31, 2024 78.67 Mn
Sep 30, 2024 78.51 Mn
Jun 30, 2024 74.58 Mn
Mar 31, 2024 81.05 Mn
Dec 31, 2023 78.05 Mn
Sep 30, 2023 79.67 Mn
Jun 30, 2023 77.26 Mn
Mar 31, 2023 80.46 Mn
Dec 31, 2022 102.48 Mn
Dec 31, 2021 44.73 Mn
Sep 30, 2021 38.96 Mn
Jun 30, 2021 19.58 Mn
Dec 31, 2020 15.79 Mn